Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JT001 in Elderly Chinese Subjects
NCT06093308Phase 1Completed
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deuremidevir in coronavirus disease 2019 (COVID-19), sponsored by Shanghai Vinnerna Biosciences Co., Ltd. Primary endpoints: Severity of Serious Adverse Events, Number of Participants with Serious Adverse Events and 5 more. Started Jul 2023; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06093308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093308.